Prize money isn't the best way to increase productivity and drug development, especially when the success of a program is relatively random.

FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.

The new trend for digital health solutions? A patient-centered approach to treatment.

What questions remain for digital health entrepreneurs in an uphill battle for innovation?

The real answer to innovation in the healthcare industry will be found in a technology company  willing to recognize the complexities and humanity inherent to healthcare.

Here’s a heretical statement: We don’t spend enough money on high-priced cancer drugs.

Even with the coming of a new drug reimbursement environment that emphasizes profound innovation, don't expect to see the end of incremental  biopharma innovation just yet.

The decision by Angelina Jolie to undergo a double mastectomy after tests determined she carried a genetic mutation that elevated her chances of developing breast or ovarian cancer has led to renewed calls for expanded genetic screening. It has also raised a disconcerting question-could genetic testing actually be harmful to your health?

As drug companies take divergent strategies focused either on research or cutting costs, what might this mean for the path future companies take in the pharmaceutical industry?

High-profile technology companies are revered by society while pharmaceutical companies developing life-saving technologies are viewed with contempt; why the disparity?